文献速递眼底病与葡萄膜炎

法瑞西单抗与阿柏西普治疗糖尿病黄斑水肿的真实世界早期结局

Real-world early outcomes of intravitreal faricimab 6-mg and aflibercept 2-mg injection in diabetic macular oedema.
PubMed 文献 · Br J Ophthalmol · 2026-04-28

这项回顾性平行队列研究纳入Moorfields眼科医院300例糖尿病黄斑水肿患者,比较法瑞西单抗6mg与阿柏西普2mg负荷期治疗的4个月结局。两组视力和黄斑中心凹厚度改善相近,调整后差异均无统计学意义,基线视力、基线黄斑中心凹厚度和治疗间隔是主要预测因素。

要点

  • 法瑞西单抗与阿柏西普治疗DMO的4个月视力和解剖结局相当。
  • 基线视力较低者视力增益更大,基线CST较高者解剖改善更明显。
  • 治疗间隔影响功能反应,及时治疗很重要。

核心结论

  • 法瑞西单抗与阿柏西普治疗糖尿病黄斑水肿的短期解剖和功能结局相当。
  • 基线视力较低者视力增益更大,基线CST较高者解剖改善更明显。
  • 治疗间隔影响功能反应,早期结局主要由基线疾病特征和治疗依从性决定,而非药物选择。

研究设计与样本

  • 回顾性平行队列比较研究,纳入Moorfields眼科医院300例连续糖尿病黄斑水肿患者。
  • 纳入初治或至少6个月未治疗并随后开始法瑞西单抗或阿柏西普2mg负荷期治疗的眼睛,随访4个月。
  • 最终分析292眼(阿柏西普191眼,法瑞西单抗101眼),246眼(84.2%)完成随访。

主要发现

  • 未调整平均视力增益:阿柏西普+3.9±10.4字母,法瑞西单抗+5.2±11.8字母。
  • 调整后边际平均视力增益:阿柏西普+4.2字母,法瑞西单抗+4.7字母,差异-0.5字母(p=0.7)。
  • 未调整平均CST降低:阿柏西普87.3±106.1 µm,法瑞西单抗113.1±136.7 µm。
  • 调整后平均CST降低:阿柏西普95.4 µm,法瑞西单抗99.8 µm,差异-4.4 µm(p=0.7)。
  • 基线视力和治疗间隔是功能反应的显著预测因素,基线视力影响约为治疗间隔的3.4倍;基线CST是解剖反应的唯一独立预测因素。

临床怎么用

  • 对于糖尿病黄斑水肿,法瑞西单抗与阿柏西普均可作为负荷期治疗选择,短期疗效相近。
  • 应重视基线视力、基线CST和治疗间隔对早期结局的影响,确保及时治疗和依从性。

局限性

  • 回顾性研究设计,随访仅4个月,样本来自单一中心,法瑞西单抗组样本量较小。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND/AIMS: To evaluate real-world, short-term anatomical and functional outcomes of faricimab versus aflibercept 2 mg in diabetic macular oedema (DMO). METHODS: This retrospective, parallel-cohort comparative study included 300 consecutive patients with DMO from Moorfields Eye Hospital. Eligible eyes were treatment-naïve and treatment-experienced not receiving therapy for ≥6 months and subsequently initiated on loading phase of faricimab or aflibercept 2mg. Follow-up was 4 months. Data were collected from the Moorfields electronic medical records system. Changes in visual acuity (VA) and central subfield thickness (CST) from baseline to the fourth injection were analysed using multiple linear regression adjusted for baseline covariates (age, gender, ethnicity, diabetes type, baseline retinopathy status, baseline VA or CST and treatment interval). RESULTS: Of 300 eyes enrolled, 292 were ultimately analysed (191 aflibercept; 101 faricimab), with 246 eyes (84.2%) completing follow-up. Mean unadjusted VA gain was +3.9±10.4 letters with aflibercept and +5.2±11.8 letters with faricimab. Adjusted marginal mean VA gain was +4.2 letters for aflibercept and +4.7 letters for faricimab, with a non-significant difference of -0.5 letters (p=0.7). Baseline VA and treatment interval were significant predictors of functional response, with baseline VA exerting approximately 3.4 times the impact of treatment interval. Mean CST reduction was 87.3±106.1 µm with aflibercept and 113.1±136.7 µm with faricimab. Adjusted mean reductions were 95.4 µm and 99.8 µm, respectively (difference -4.4 µm, p=0.7). Baseline CST was the only independent predictor of anatomical response. CONCLUSION: Faricimab and aflibercept achieved comparable short-term anatomical and functional outcomes, with greater anatomical improvement associated with higher baseline CST and larger visual gains observed with lower baseline VA. Treatment interval influenced functional response, underscoring the importance of timely therapy. Baseline disease features and treatment adherence are key determinants of early outcomes, rather than drug selection.

来源:Br J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Chalkiadaki E, Sim SY, Williams O, et al. Real-world early outcomes of intravitreal faricimab 6-mg and aflibercept 2-mg injection in diabetic macular oedema. Br J Ophthalmol. 2026. PMID: 42014182. doi:10.1136/bjo-2025-328893

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。